The Exanta regulatory submission for prevention of stroke in atrial fibrillation, which remains on track in Europe and the US, also includes SPORTIF V and other trials in the extensive clinical trial programme.

Exanta is set to be the first new fixed-dose oral anticoagulant since the introduction of warfarin over 50 years ago and is currently being investigated in an extensive clinical trials programme for a number of key indications.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $17.8 billion and leading positions in sales of gastrointestinal, oncology, anaesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.